Eli Lilly to acquire Bothell’s Curevo Vaccine for $1.5 billion - The Seattle Times
Earnings
Eli Lilly is acquiring three vaccine developers including Curevo Vaccine for a combined ~$20B as it pushes into infectious disease. The deal signals a strategic pivot beyond GLP-1 dominance, but near-term EPS dilution and insider selling create a nuanced setup rather than a clean breakout.
0 reads·0 theses
Angle
↓ SHORT-5% target+4% stop2-4 weeks
Fade the LLY M&A pop near-term — $20B spending spree with insider selling and no disclosed price target suggests the street needs time to underwrite the new strategy.